Health
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK, February 17, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically si
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/b751fc2f7dd4c5d463e36ed4db929077"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nFXbNW55eZCFy9QdzHXwqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b751fc2f7dd4c5d463e36ed4db929077","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancer","length":190,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results reinforce potential of BRAFTOVI as a cornerstone targeted treatment, if this regimen is approved","length":104,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"NEW YORK, February 17, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically significant and clinically meaningful improvement in PFS, a key secondary endpoint, as assessed by blinded independent central review (BICR) compared to treatment with FOLFIRI with or without bevacizumab. Overall survival (OS), a descriptive secondary endpoint, also showed clinically meaningful prolonged improvement with the BRAFTOVI regimen.","length":859,"tagName":"p"},{"type":"text","content":""These results build on the positive objective response rate data we recently shared, providing further evidence of the meaningful benefit this BRAFTOVI-based targeted approach may offer patients with BRAF V600E–mutant metastatic colorectal cancer," said Jeff Legos, Chief Oncology Officer, Pfizer. "The combination of significant responses and now improvement in progression‑free survival und...